Shire and Novimmune, a Geneva, Switzerland-based biopharmaceutical company focused on antibody-based medicines, have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize a bispecific antibody now in preclinical development for treating hemophilia A and hemophilia A patients with inhibitors.

Shire is leading the development of the program to optimize and evaluate a fully-human, bispecific IgG antibody targeting FIXa and FX, designed to imitate the body’s natural mechanism of Factor VIII-driven coagulation, according to Shire. Novimmune has been developing a platform for making fully human, bispecific antibodies and has several in-house programs targeting tumor associated antigens and the immune system checkpoint protein CD47.

Source: Shire and Novimmune